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Dear Sir,
Bouallal et al1 have touched on an important
therapeutic dilemma in patients with reduced right
ventricular function supporting systemic circulation. As they have mentioned, there exist no
randomised clinical trial showing the benefit of
beta-blockade in this group of patients. Hence, the
recommendation to treat these patients with betablockers remains without any evidence.
We recently published the results of a prospective, randomised, double-blind, placebo-controlled
trial of beta-blockade on patients with operated
tetralogy of Fallot and could not demonstrate a
significant positive effect on right or left ventricular
size and function, cardiorespiratory exercise capacity, or quality of life.2
Despite there being fundamental differences in
the pathophysiology of right ventricular volume
overload – e.g. in post-operative patients with
tetralogy of Fallot – and right ventricular pressure
overload in patients with the morphologic right
ventricle functioning as the systemic ventricle,
obviously the effect of beta-blockade on the right
ventricle seems to be different from the effect on the
left ventricle.3
We would like to address several methodological
concerns in the paper by Bouallal et al1. There is no
established gold standard for non-invasive assessment of the right ventricle. The most reliable
method is cardiac magnetic resonance imaging.
Radionuclide ventriculography is an alternative
method for this purpose, but it is less reliable
than cardiac magnetic resonance imaging, especially
in patients with right ventricular overload after
surgery for congenital cardiac disease. Nichols et al4
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therefore recommend that cardiac magnetic resonance
imaging should be the first choice for evaluating
patients with congenital cardiac disease. In the paper
published by Bouallal et al1, the assessment of right
ventricle (pre- and post-beta blocker therapy) was
done based on cardiac magnetic resonance imaging
(in 10 patients) and Radionuclide ventriculography
(in eight patients). Despite cardiac magnetic resonance
imaging showing no change in right ventricular
ejection fraction, Radionuclide ventriculography
showed an improvement in ejection fraction from
41% to 49% (p 5 0.031). Including two different
methods for assessment of right ventricular function is
per se problematic, but the question remains which
method is more reliable and which results should
be emphasised. The neurohumoral status of these
patients remained unchanged, as reflected by the
brain natriuretic peptide level, and hence it is difficult
to attribute the improvement in ejection fraction
as measured by Radionuclide ventriculography to
remodelling of the right ventricular myocardium due
to beta blockade.
Despite the study showing some improvement
in subjectively felt physical activity, based on the
New York Heart Association classification and Ability
index, objectively measured cardiopulmonary capacity remains unchanged. Owing to the nature of
study (not placebo controlled), it is impossible to
rule out a placebo effect.
If there remains a positive clinical effect that is
not explained by better myocardial function or
exercise capacity, the question is what it is. In our
opinion, these beneficial effects that we also
observed in our placebo-controlled study may be
caused by effects of beta-blocker therapy on the
autonomic nervous system. Probably these effects
could potentially be revealed by analysis of heart
rate variability. Unfortunately, these data are not
available in patients with congenital cardiac disease.
Last but not least, although appropriate statistical methods were employed, the small number of
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patients remains a concern, but the bigger question
is whether the changes are clinically meaningful
and/or generalisable.
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